A Mouse Monoclonal Antibody against Epstein‐Barr Virus Envelope Glycoprotein 350 Prevents Infection Both In Vitro and In Vivo | Zendy

Tanzina Haque | Zendy; Ingólfur Johannessen | Zendy; Dilani Dombagoda | Zendy; Chandrya Sengupta | Zendy; David Burns | Zendy; Pru Bird | Zendy; G Hale | Zendy; Giorgina MieliVergani | Zendy; Dorothy H. Crawford | Zendy

Open Access

A Mouse Monoclonal Antibody against Epstein‐Barr Virus Envelope Glycoprotein 350 Prevents Infection Both In Vitro and In Vivo

Author(s) -

Tanzina Haque,

Ingólfur Johannessen,

Dilani Dombagoda,

Chandrya Sengupta,

David Burns,

Pru Bird,

G Hale,

Giorgina MieliVergani,

Dorothy H. Crawford

Publication year - 2006

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/505912

Subject(s) - monoclonal antibody , in vivo , epstein–barr virus , peripheral blood mononuclear cell , in vitro , virus , immunology , virology , antibody , glycoprotein , biology , monoclonal , microbiology and biotechnology , biochemistry

A mouse monoclonal antibody (MAb) against Epstein-Barr virus (EBV) envelope glycoprotein 350, 72A1, inhibited EBV infection of B lymphocytes in vitro. When severe combined immunodeficient mice were injected with EBV-seronegative donors' peripheral-blood mononuclear cells and challenged with EBV, 72A1 MAb prevented development of EBV-positive tumors: none of the test mice (0/12) developed EBV-positive tumors. In contrast, 67% (8/12) of control mice developed EBV-positive tumors (P=.001). Purified 72A1 MAb was infused into 1 healthy adult and 4 EBV-seronegative children after liver transplant. No adverse reactions were seen in the adult or in 3 of the transplant recipients. The remaining patient developed a hypersensitivity reaction, thus underlining the need to humanize the MAb.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research